“Final” data on abiraterone acetate in treatment of chemo-naive mCRPC

According to a media release issued on Sunday, the most recent “final” update to the COU-AA-302 trial has shown that treatment with abiraterone + prednisone provided a statistically significant overall survival benefit in the treatment of men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Bill Manning’s blog: Part VI

Here is the sixth of Bill’s blog posts. He, and we, hope it will be helpful to all those battling late stage prostate cancer as he takes advantage of some of the new drugs that have come to market over the past couple of years. Click here for earlier parts if you missed them. … READ MORE …

ADT and incidence of bone fractures on in the “real world”

Recent data from the Prostate Cancer Outcomes Study, which followed men diagnosed with prostate cancer for a total of 15 years after their diagnosis, have provided us with valuable information about risk for bone fractures in men with progressive disease. … READ MORE …

Dose of radiation, survival, and side effects in intermediate-risk prostate cancer

There were a lot of data presented at the recent annual meeting of the American Society for Radiation Oncology (ASTRO) in San Francisco. Much of the data regarding prostate cancer was of relatively minor significance … but one paper seems to be of considerable importance. … READ MORE …

What is PI-RADS and why should you care?

PI-RADS is an acronym and it stands for “prostate imaging — reporting and data system” but what it really is is a highly structured method for reporting what can be seen on certain types of prostate-specific magnetic resonance imaging (MRI) scan and how to interpret these data. … READ MORE …

Seven critical prostate cancer controversies

Long-time prostate cancer advocates (and of course all members of the clinical treatment community) are well aware of the controversies that complicate testing for, diagnosing, and managing prostate cancer. However, for men approaching their mid 40s and early 50s and newly diagnosed patients this can come as a major shock. … READ MORE …

Data from early access trial of abiraterone acetate in post-chemo mCRPC

A new article in The Lancet Oncology has provided us with data from the early access trial of abiraterone acetate + predisone conducted in men with post-chemotherapy, metastatic, castration-resistant prostate cancer (mCRPC) in a total of 23 countries around the world. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,152 other followers